Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | HPGDS | O60760 | 4/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27039598 | 0.94 | CRBN (0.60) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL25265619 | 0.91 | CRBN (0.69) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL27008964 | 0.91 | CRBN (0.69) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL25201075 | 0.91 | CRBN (0.69) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL30441764 | 0.91 | CRBN (0.69) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL25550938 | 0.90 | CRBN (0.70) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL26814197 | 0.89 | CRBN (0.70) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL27039543 | 0.87 | CRBN (0.63) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL23173710 | 0.87 | CRBN (0.68) | CRBNHPGDSDDB1IKZF3ALDH1A1 | |
| SCHEMBL30144633 | 0.86 | CRBN (0.76) | CRBNHPGDSDDB1IKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | CRBN 184/4885HPGDS 3165/4885DDB1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.